“Latest Stem Cells News”

A DRUG said to cure diabetes could mean that sufferers will no longer need to take daily insulin injections.
The treatment uses stem cells made from human bone marrow and has been tested on patients suffering from Type 1 diabetes – which affects about 900,000 people in Britain.

Diabetes causes the immune system to attack the pancreas, the organ that makes insulin, which then controls blood-sugar levels.
Sufferers must take insulin injections to stay alive because if blood-sugar levels are allowed to rise too high or get too low, they could fall into a coma and die.
But early trials by American scientists have shown that the drug Prochymal can stop the immune system destroying the pancreas.
It is hoped the drug could be on the market in less than two years.

Professor Aaron Vinik, a hormone specialist in Norfolk, Virginia, said the cure could change diabetes sufferers’ lives.
He said: “This is a very exciting discovery.
Shock “When people get told they have diabetes, it comes as a tremendous shock.
“They have to live with having to take insulin injections for the rest of their lives.

“In future, we will have a cure that will stop the disease in its tracks.”
Prochymal has proved effective because stem cells in the drug form a barrier to protect the pancreas from attack. This allows the organ to recover and to continue making insulin.
The stem cells are taken from volunteers and then multiplied in the lab to produce hundreds of millions of cells.
In early tests, patients have been given three infusions of the cells into their bloodstream over 60 days.

It has been tested on 60 patients with early diabetes.
Those already on insulin were able to reduce the amount as the stem cells started saving the pancreas.
Prof Vinik said most patients would still need insulin at first but would probably be off it “in a matter of months”.

from Daily record

Incoming search terms:

Image via Wikipedia

Researchers funded by the National Institutes of Health have converted stem cells from the human endometrium into insulin-producing cells and transplanted them into mice to control the animals’ diabetes.

The endometrium, or uterine lining, is a source of adult stem cells. Normally, these cells generate uterine tissue each month as part of the menstrual cycle. Like other stem cells, however, they can divide to form other kinds of cells.

The study’s findings suggest the possibility that endometrial stem cells could be used to develop insulin-producing islet cells. These islet cells could then be used to advance the study of islet cells transplantation as a treatment for people with diabetes. If the transplantation of islet cells derived from endometrial cells is perfected, the study authors write that women with diabetes could provide their own endometrial tissue for such a transplant, sidestepping the chance of rejection posed by tissue from another person. Endometrial stem cells are readily available and can be collected easily during a simple outpatient procedure. Endometrial tissue could also be collected after hysterectomy, the surgical removal of the uterus.

“The study findings are encouraging,” said Louis V. DePaolo, Ph.D., chief of the Reproductive Sciences Branch at the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which funded the study. “Research to transplant insulin-producing cells into patients with diabetes could proceed at a much faster pace with a relatively accessible source of donor tissue.”

The study authors note that such a treatment would be more useful for people with Type 1 diabetes, in which no insulin is produced. The treatment would be less useful for Type 2 diabetes, in which insulin is usually produced, but in which cells have difficulty using the insulin that is available.

The findings appear in Molecular Therapy. The study was conducted by Xavier Santamaria, Efi E. Massasa, Yuzhe Feng, Erin Wolff and Hugh Taylor, M.D., all of Yale University, New Haven, Conn.

Incoming search terms:

A particular type of stem cell transplantation using the patient’s own cells led to short-term freedom from insulin injections in 20 of 23 patients newly diagnosed with type 1 diabetes participating in an experimental protocol in Brazil.

One patient even managed to go four years without needing outside sources of insulin, although the average was 31 months, said the authors of a report in the April 15 issue of the Journal of the American Medical Association, a themed issue on diabetes.

The patients also kept their blood sugar under control, which is key to preventing complications from diabetes. And, the authors stated, increased C-peptide levels indicated that the pancreas’ beta cells were alive and well.

“We were trying to preserve islet beta cell mass, that is, the cells that produce insulin, by stopping the immune system attack on these cells,” said senior study author Dr. Richard Burt, of Northwestern University Feinberg School of Medicine in Chicago. “Why new onset? Because we wanted to make sure there were still some islets there. We don’t believe stem cells form islet cells, but if the islet cells are still there, there might be regeneration if we stop the attack soon enough.”

Incoming search terms:

Hundreds of thousands of people suffer from hereditary diabetes, a condition that destroys cells in the pancreas and leaves the body unable to regulate blood sugar levels.
Sufferers are forced to inject themselves with insulin everyday and adopt special diets to cope with the irreversible condition.

But now scientists claim a cure could be developed after cells in the liver were converted to insulin producers in research on mice.
They believe the process, described in the journal Developmental Cell, could one day lead to a permanent one-off cure for the disease.

Incoming search terms: